The debate over Synthroid versus Armour Thyroid divides doctors because the two medications represent fundamentally different philosophies of treatment — and a landmark 2025 study has thrown gasoline on an already heated argument. Synthroid delivers synthetic T4 only, backed by FDA approval and guideline endorsements from the American Thyroid Association. Armour Thyroid, derived from desiccated pig thyroid glands, provides both T4 and T3 hormones and has been prescribed since the 1800s — yet has never received formal FDA approval. Now, with the FDA threatening to pull Armour from the market by August 2026, both patients and physicians face an urgent reckoning. What makes this debate particularly relevant to brain health is a massive study published in the Journal of Clinical Endocrinology & Metabolism in June 2025.
Researchers at the University of Texas Medical Branch analyzed over 4.5 million patients and found that combination therapy containing T3 — the kind found in Armour Thyroid — was associated with a 27% lower risk of dementia compared to levothyroxine alone. That single finding has complicated the clean narrative that Synthroid is always the better choice. This article breaks down what each drug actually contains, what the clinical evidence shows, how the FDA’s regulatory deadline could reshape treatment options, and what all of this means for people concerned about cognitive decline. For caregivers and families navigating dementia risk, thyroid management is not a peripheral concern. Hypothyroidism is one of the treatable conditions linked to cognitive impairment, and the question of which thyroid medication to use may carry consequences that extend well beyond metabolism.
Table of Contents
- What Exactly Are Synthroid and Armour Thyroid, and Why Do Doctors Disagree?
- The 2025 Dementia Study That Changed the Conversation
- The FDA’s Regulatory Crackdown and the August 2026 Deadline
- Comparing Cost, Access, and Practical Tradeoffs
- The Genetic Factor Most Doctors Do Not Test For
- What the Discontinuation Rates Actually Tell Us
- Where This Debate Goes From Here
- Conclusion
- Frequently Asked Questions
What Exactly Are Synthroid and Armour Thyroid, and Why Do Doctors Disagree?
Synthroid, the brand name for levothyroxine, is a synthetic version of the T4 thyroid hormone. It is FDA-approved, manufactured under strict quality controls, and delivers consistent dosing from one batch to the next. The American Thyroid Association and the American Association of Clinical Endocrinology both recommend it as first-line treatment for hypothyroidism. For the majority of endocrinologists trained in the past three decades, Synthroid is the default and often the only option they consider. Armour Thyroid is a different animal — literally. It is made from desiccated pig thyroid glands and contains both T4 and T3 hormones. Proponents argue this better mimics human thyroid function, since a healthy thyroid gland naturally produces both hormones.
Critics counter that the T4-to-T3 ratio in pig thyroid does not match human physiology, and that batch-to-batch consistency is harder to guarantee with an animal-derived product. The core disagreement comes down to whether providing T3 directly offers meaningful clinical benefit, or whether the human body’s natural conversion of T4 to T3 is sufficient for most patients. The divide is not just scientific — it is also cultural. Many integrative and functional medicine practitioners champion Armour Thyroid based on patient-reported improvements in energy, mood, and mental clarity. Many conventional endocrinologists view those reports as anecdotal and point to the higher adverse effect rates seen in clinical studies. A retrospective study of 250 patients found that 8.8% of Armour Thyroid users experienced adverse effects compared to 3.2% on levothyroxine, and 19.2% of Armour patients discontinued the medication within six months versus just 4.0% of levothyroxine patients. The top reasons for stopping Armour included no symptom improvement, palpitations, and worsening anxiety.
The 2025 Dementia Study That Changed the Conversation
In June 2025, researchers at the University of Texas Medical Branch published what may be the most consequential thyroid study in years. Using the TriNetX database, they analyzed data from more than 4.5 million patients across 126 healthcare organizations in 17 countries. Their findings were striking: hypothyroid patients had a 1.4 times higher risk of dementia and double the mortality rate even when their TSH levels were brought into normal range with levothyroxine alone. The more provocative finding was what happened when T3 was added to the equation. Patients on combination therapy — either levothyroxine plus liothyronine (synthetic T3) or desiccated thyroid extract like Armour — had a 27% lower risk of dementia and a 31% lower risk of mortality compared to those on levothyroxine alone. For a field that has long dismissed T3 supplementation as unnecessary, these numbers were difficult to ignore.
However, this study has important limitations that warrant caution. It was observational, not a randomized controlled trial, which means it cannot prove that combination therapy directly caused the reduced dementia risk. There may be confounding factors — for instance, patients who sought out combination therapy may have been more health-conscious overall, or may have had access to more attentive medical care. The study also did not distinguish between different doses or formulations of combination therapy. Still, at a scale of 4.5 million patients, the signal is strong enough that dismissing it outright would be intellectually dishonest. For families already managing or trying to prevent dementia, this study raises questions worth discussing with a physician.
The FDA’s Regulatory Crackdown and the August 2026 Deadline
On August 7, 2025, the FDA announced that desiccated thyroid extract products, including Armour Thyroid, lack approved biologics license applications and cannot legally be marketed as biologic drugs. This was not a sudden decision — the regulatory gray area surrounding these medications has existed for decades. But the formal enforcement notice set a 12-month transition period, meaning manufacturers must either obtain proper approval or face removal from the market by August 2026. AbbVie, which manufactures Armour Thyroid, has been working to meet this deadline. The company launched a large clinical study called AVANTI in April 2024 to generate the data needed for an FDA approval application. If AVANTI produces favorable results and AbbVie’s application is accepted, Armour Thyroid could become the first desiccated thyroid product to receive formal FDA approval — which would, ironically, undermine one of the strongest arguments against it.
But if AbbVie fails to secure approval in time, Armour Thyroid could disappear from U.S. pharmacies entirely. Other desiccated thyroid products have already fallen. Nature-Throid and WP Thyroid were discontinued in 2024, leaving Armour Thyroid as essentially the last standing DTE option. The American Association of Clinical Endocrinology has publicly supported the FDA’s actions, framing them as a necessary step to ensure patients receive properly vetted medications. For the estimated hundreds of thousands of Americans currently taking Armour Thyroid, the August 2026 deadline is not an abstract regulatory matter — it is a countdown that could force a medication change whether they want one or not.
Comparing Cost, Access, and Practical Tradeoffs
Cost is a real factor in this debate, and the numbers may surprise people on both sides. Generic levothyroxine is remarkably affordable, running roughly $4 to $25 per month for 30 tablets, with GoodRx coupons bringing prices as low as $2.48. Brand-name Synthroid is considerably more expensive at approximately $70 per month without insurance, though eligible insured patients can pay as little as $25 per month with a manufacturer savings card. Armour Thyroid falls in between, at roughly $45 to $50 per month (based on approximately $135 to $150 for a 90-day supply), with GoodRx coupons bringing the price down to around $108 for 90 tablets. Insured patients may pay about $35 per month with a savings card. The cost comparison is more nuanced than it first appears, though.
Some patients on levothyroxine alone end up adding a separate prescription for liothyronine (synthetic T3) if their doctor agrees to combination therapy, which adds another $10 to $30 per month depending on the pharmacy and insurance coverage. In that scenario, the total cost of synthetic combination therapy can approach or exceed the cost of Armour Thyroid. The practical tradeoff extends beyond price. Synthroid’s advantage is predictability — consistent dosing, widespread availability, and the confidence that comes with formal FDA approval. Armour’s advantage, for those who respond well to it, is simplicity — one pill containing both hormones rather than managing two separate prescriptions. But if Armour is pulled from the market in 2026, patients currently benefiting from it will need to work with their doctors to find an alternative, whether that means synthetic combination therapy or levothyroxine alone.
The Genetic Factor Most Doctors Do Not Test For
One of the most compelling arguments for T3-containing therapy involves a genetic variant that many physicians do not routinely screen for. The DIO2 gene encodes the enzyme responsible for converting T4 into the active T3 hormone in tissues throughout the body, including the brain. Some patients carry polymorphisms in this gene that impair that conversion process, meaning they may produce less T3 from a given dose of T4 than the average person. For these patients, levothyroxine monotherapy may normalize blood test results — TSH looks fine, T4 levels look fine — while tissues remain relatively T3-depleted.
This could help explain why some hypothyroid patients continue to report brain fog, fatigue, and cognitive difficulties despite having “normal” lab work. The 2025 UTMB study’s finding that combination therapy reduced dementia risk even in patients with normal TSH levels is consistent with this theory, though the study did not specifically test for DIO2 status. The limitation here is significant: genetic testing for DIO2 polymorphisms is not yet standard practice, and there are no established clinical guidelines for adjusting thyroid treatment based on genotype. A patient who suspects they are a poor T4-to-T3 converter cannot simply demand Armour Thyroid and expect their endocrinologist to agree. But the growing body of evidence — including the dementia data — suggests this is an area where personalized medicine may eventually replace the current one-size-fits-all approach.
What the Discontinuation Rates Actually Tell Us
The retrospective study of 250 patients offers a useful reality check for both sides of the debate. The 19.2% discontinuation rate for Armour Thyroid within six months — compared to just 4.0% for levothyroxine — is frequently cited by Synthroid advocates as evidence that Armour is poorly tolerated. And the reasons for discontinuation are telling: 37.5% stopped because they saw no symptom improvement, 20.8% experienced palpitations, and 12.5% reported worsening anxiety.
But a separate randomized double-blind crossover study of 70 patients tells a different story. In that trial, patients on desiccated thyroid extract showed more weight loss and reported higher treatment satisfaction, even though biochemical outcomes were similar between groups. Taken together, these studies suggest that Armour Thyroid works well for a subset of patients but poorly for others — and that the challenge is identifying which group a given patient belongs to before starting treatment, rather than assuming one medication is universally superior.
Where This Debate Goes From Here
The next 18 months will likely determine the future of this debate in the United States. If AbbVie’s AVANTI study demonstrates safety and efficacy and Armour Thyroid receives FDA approval, the medication will gain the regulatory legitimacy it has always lacked. Doctors who dismissed it primarily on the grounds of its unapproved status would need to reassess.
If Armour is pulled from the market, the conversation shifts to whether synthetic combination therapy — levothyroxine plus liothyronine — can fill the gap, and whether insurers will cover it. For the dementia and brain health community specifically, the 2025 UTMB study has opened a door that will be difficult to close. A 27% reduction in dementia risk is not a trivial number, and larger prospective trials will almost certainly follow. The question is no longer whether T3 matters for brain health — the question is how to deliver it safely, consistently, and affordably to the patients who need it most.
Conclusion
The Synthroid versus Armour Thyroid debate persists because both sides have legitimate evidence backing their position. Synthroid offers FDA approval, consistent dosing, lower adverse effect rates, and endorsement from major medical societies. Armour Thyroid and other T3-containing therapies offer the potential for better cognitive outcomes, improved patient satisfaction, and a more complete hormonal replacement — advantages that the 2025 UTMB dementia study has made harder to dismiss.
For anyone concerned about brain health, the practical takeaway is this: talk to your doctor about whether your current thyroid treatment is truly optimized, not just for your blood work but for your cognitive function. Ask about T3 levels, inquire about DIO2 genetic testing if you have persistent symptoms despite normal TSH, and stay informed about the FDA’s August 2026 deadline. Thyroid management is not a set-it-and-forget-it proposition, and the science is moving faster than the guidelines.
Frequently Asked Questions
Is Armour Thyroid being taken off the market?
It could be. The FDA announced in August 2025 that Armour Thyroid lacks formal approval as a biologic drug. AbbVie is conducting the AVANTI clinical study to seek approval, but if that effort fails by August 2026, Armour Thyroid could be removed from U.S. pharmacies.
Can hypothyroidism cause dementia?
Research suggests a connection. A 2025 study of over 4.5 million patients found that hypothyroid patients had a 1.4 times higher risk of dementia even with normal TSH levels on levothyroxine. Combination therapy including T3 was associated with a 27% lower dementia risk.
Is generic levothyroxine the same as brand-name Synthroid?
They contain the same active ingredient, but some patients and physicians report differences in how they are absorbed or tolerated. Generic levothyroxine costs as little as $4 per month, while brand-name Synthroid runs about $70 per month without insurance.
What is the DIO2 gene and why does it matter?
The DIO2 gene controls an enzyme that converts T4 into active T3 in your tissues, including the brain. Some people carry genetic variants that impair this conversion, which may explain why they feel poorly on T4-only therapy despite normal lab results.
Are there alternatives to Armour Thyroid if it is discontinued?
Yes. Doctors can prescribe synthetic combination therapy using levothyroxine plus liothyronine (synthetic T3). This approach provides both hormones without relying on an animal-derived product, though it requires managing two separate prescriptions.
